Laboratorios Farmaceuticos Rovi, S.A. (LON:0ILL)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 2.55B +6.9% |
| Revenue (ttm) | 665.66M +3.2% |
| Net Income | 159.46M +40.0% |
| EPS | 3.12 +39.9% |
| Shares Out | n/a |
| PE Ratio | 15.99 |
| Forward PE | 19.91 |
| Dividend | 0.67 (1.34%) |
| Ex-Dividend Date | Jul 13, 2026 |
| Volume | 65 |
| Open | 58.20 |
| Previous Close | 58.05 |
| Day's Range | 56.90 - 58.35 |
| 52-Week Range | 52.45 - 87.50 |
| Beta | 0.23 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 23, 2026 |
About LON:0ILL
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Expr... [Read more]
Financial Performance
In 2025, LON:0ILL's revenue was 743.48 million, a decrease of -2.65% compared to the previous year's 763.75 million. Earnings were 140.44 million, an increase of 2.60%.
Financial numbers in EUR Financial StatementsNews
Laboratorios Farmaceuticos Rovi Earnings Call Transcript: Q2 2026
Revenue grew 13% to EUR 357 million in H1 2026, driven by CDMO expansion and Phoenix acquisition. EBITDA rose 85% (down 10% excluding badwill), and net profit more than doubled. Guidance for 2026 is maintained, with improved outlook for heparins and strong Okedi momentum.
Laboratorios Farmaceuticos Rovi Slides: Q2 2026
Laboratorios Farmaceuticos Rovi has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
Laboratorios Farmaceuticos Rovi Earnings release: Q2 2026
Laboratorios Farmaceuticos Rovi released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
Laboratorios Farmaceuticos Rovi Quarterly report: Q2 2026
Laboratorios Farmaceuticos Rovi has published its Q2 2026 quarterly earnings report on July 23, 2026.
Laboratorios Farmaceuticos Rovi Earnings Call Transcript: Q1 2026
Q1 2026 saw flat revenues and higher gross margins, but heparin sales declined amid pricing pressure and high inventories. CDMO growth was positive but full-year guidance was revised down due to contract delays, while R&D investment remains high and long-term targets are unchanged.
Laboratorios Farmaceuticos Rovi Slides: Q1 2026
Laboratorios Farmaceuticos Rovi has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Laboratorios Farmaceuticos Rovi Earnings release: Q1 2026
Laboratorios Farmaceuticos Rovi released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Laboratorios Farmaceuticos Rovi Earnings Call Transcript: Q4 2025
2025 saw resilient performance with revenue of EUR 756.1 million and EBITDA up 4%, driven by Specialty Pharma growth and cost efficiencies, despite a CDMO sales decline. 2026 guidance targets high single- to low double-digit revenue growth, with major investments and R&D ramp-up planned.
Laboratorios Farmaceuticos Rovi Slides: Q4 2025
Laboratorios Farmaceuticos Rovi has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 25, 2026.
Laboratorios Farmaceuticos Rovi Annual report: Q4 2025
Laboratorios Farmaceuticos Rovi has published its Q4 2025 annual report on February 25, 2026.
Laboratorios Farmaceuticos Rovi Earnings release: Q4 2025
Laboratorios Farmaceuticos Rovi released its Q4 2025 earnings on February 25, 2026, summarizing the period's financial results.
Laboratorios Farmaceuticos Rovi Earnings release: Q3 2025
Laboratorios Farmaceuticos Rovi released its Q3 2025 earnings on November 6, 2025, summarizing the period's financial results.
Laboratorios Farmaceuticos Rovi Slides: Q3 2025
Laboratorios Farmaceuticos Rovi has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 6, 2025.
Laboratorios Farmaceuticos Rovi Transcript: Investor Update
A major U.S. manufacturing site acquisition adds advanced injectable capacity, a five-year $50 million annual contract with BMS, and significant expansion potential. The site will boost global CDMO capabilities, with new lines operational by 2027 and long-term profitability expected as new customers are onboarded.
Laboratorios Farmaceuticos Rovi Slides: Investor Update
Laboratorios Farmaceuticos Rovi has posted slides in relation to its latest quarterly earnings report, which was published on September 30, 2025.